Mark C Munson

This inventor holds 35 USPTO granted patents and 14 published patent applications, plus 7 CIPO patents and 10 EPO patents, primarily in Kinase Inhibitors. Top assignees: Array Biopharma Inc., Genzyme Corporation, Sanofi. Active years: 2002-2026.

USPTO Granted Patents = 35 (Patent Applications = 14)

% Patents Active = 71.4

CIPO Patents = 7 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 8.5

ph-index = 7

Forward Citations = 552(Granted Patents)

Location History:

Louisville, CO (US) (2002 - 2014)
Boulder, CO (US) (2010 - 2015)
Acton, MA (US) (2014 - 2020)
Bridgewater, NJ (US) (2021)

Company Filing History:

Sionna Therapeutics Inc.

patents

6. 1 out of 44

Celgene Avilomics Research, Inc.

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

PIM Kinase

Receptor Tyrosine Kinase

Protein Kinase

Arylamides

Macrocyclic Compounds

UDP Glycosyltransferase

Heteroaryl Compounds

Triazolopyridine

Substituted Pyrido

Indazol Compounds

P38 Inhibitors

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12649750 - Macrocyclic compounds, compositions, and methods of using thereof (2026-06-09),

2. 12637414 - Arylamides and methods of use thereof (2026-05-26),

3. 12630521 - Arylamides and methods of use thereof (2026-05-19),

4. 12630498 - Arylamides and methods of use thereof (2026-05-19),

5. 12624051 - Macrocyclic compounds, compositions, and methods of using thereof (2026-05-12),

6. 12583824 - 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity (2026-03-24),

7. 11098056 - UDP glycosyltransferase inhibitors and methods of use (2021-08-24),

8. 10774052 - Heteroaryl compounds and uses thereof (2020-09-15),

9. 10669269 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2020-06-02),

10. 10618902 - Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases (2020-04-14),

11. 10189794 - Heteroaryl compounds and uses thereof (2019-01-29),

12. 10065966 - Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases (2018-09-04),

13. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2017-11-07),

14. 9695132 - Heteroaryl compounds and uses thereof (2017-07-04),

15. 9663524 - Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors (2017-05-30),

Title: The Innovative Journey of Mark C Munson

Introduction: Mark C Munson is a renowned inventor based in Boulder, Colorado, known for his groundbreaking contributions to various industries.

Latest Patents: Mark C Munson holds several patents in the fields of renewable energy, sustainable technology, and consumer electronics, showcasing his versatility and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Mark C Munson has worked with leading research institutions and companies to develop cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout his career, Mark C Munson has collaborated with top engineers, scientists, and designers, bringing together diverse expertise to create innovative products that have had a lasting impact on society.

Conclusion: Mark C Munson's passion for innovation and his dedication to pushing the boundaries of technology make him a true pioneer in the world of inventions.